ArticleCost effectiveness and resource allocation : C/E2023

Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2-early breast cancer in China.

Qiran Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.